Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: Morphometric assessment of the uterus and oviduct

Ov Slayden, Mary Zelinski, K. Chwalisz, Richard Stouffer, R. M. Brenner

    Research output: Contribution to journalArticle

    86 Citations (Scopus)

    Abstract

    The long-term effects of the antiprogestin ZK 137 316 on reproductive tract morphology in rhesus macaques were investigated. The monkeys were injected daily (i.m.) for five menstrual cycles with vehicle or 0.01, 0.03 or 0.1 mg ZK 137 316/kg body weight. Reproductive tracts (n = 3/group) were collected during the mid-luteal phase (day 8) of the fifth cycle in the control, 0.01 and 0.03 mg/kg groups, or 6-7 days after the oestradiol peak in the 0.1 mg/kg group. ZK 137 316 treatment resulted in a dose-dependent atrophy of the endometrium, marked by reduced mitotic activity in the glands, compaction of the stroma, degradation of spiral arteries and dilation of veins. There was no effect of ZK 137 316 on myometrial or oviductal weight. Treatment with 0.1 and 0.03 mg/kg, but not 0.01 mg/kg resulted in fully ciliated and secretory oviducts, indicating a dose-dependent blockade of progesterone antagonism of oestrogen-dependent oviductal differentiation. In the endometrium, the suppressive action of progesterone on oestrogen and progestin receptors was also blocked by ZK 137 316 in a dose-dependent manner. However, endometrial atrophy appeared due to inhibition of progesterone action together with a blockade of oestrogen-dependent proliferation. The profoundly suppressed endometrium produced by chronic low-dose ZK 137 316 treatment is unlikely to support implantation. Such treatment may therefore provide a novel contraceptive modality.

    Original languageEnglish (US)
    Pages (from-to)269-277
    Number of pages9
    JournalHuman Reproduction
    Volume13
    Issue number2
    StatePublished - 1998

    Fingerprint

    Oviducts
    Endometrium
    Macaca mulatta
    Uterus
    Progesterone
    Atrophy
    Estrogens
    Luteal Phase
    Progesterone Receptors
    Menstrual Cycle
    Contraceptive Agents
    Estrogen Receptors
    Haplorhini
    Dilatation
    Estradiol
    Veins
    Arteries
    Body Weight
    Weights and Measures

    Keywords

    • Antiprogestin
    • Antiproliferative
    • Endometrium
    • Macaque
    • Oestrogen action

    ASJC Scopus subject areas

    • Physiology
    • Developmental Biology
    • Obstetrics and Gynecology
    • Reproductive Medicine

    Cite this

    @article{9aa7359c17f14e64b335376b19c2ea45,
    title = "Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316: Morphometric assessment of the uterus and oviduct",
    abstract = "The long-term effects of the antiprogestin ZK 137 316 on reproductive tract morphology in rhesus macaques were investigated. The monkeys were injected daily (i.m.) for five menstrual cycles with vehicle or 0.01, 0.03 or 0.1 mg ZK 137 316/kg body weight. Reproductive tracts (n = 3/group) were collected during the mid-luteal phase (day 8) of the fifth cycle in the control, 0.01 and 0.03 mg/kg groups, or 6-7 days after the oestradiol peak in the 0.1 mg/kg group. ZK 137 316 treatment resulted in a dose-dependent atrophy of the endometrium, marked by reduced mitotic activity in the glands, compaction of the stroma, degradation of spiral arteries and dilation of veins. There was no effect of ZK 137 316 on myometrial or oviductal weight. Treatment with 0.1 and 0.03 mg/kg, but not 0.01 mg/kg resulted in fully ciliated and secretory oviducts, indicating a dose-dependent blockade of progesterone antagonism of oestrogen-dependent oviductal differentiation. In the endometrium, the suppressive action of progesterone on oestrogen and progestin receptors was also blocked by ZK 137 316 in a dose-dependent manner. However, endometrial atrophy appeared due to inhibition of progesterone action together with a blockade of oestrogen-dependent proliferation. The profoundly suppressed endometrium produced by chronic low-dose ZK 137 316 treatment is unlikely to support implantation. Such treatment may therefore provide a novel contraceptive modality.",
    keywords = "Antiprogestin, Antiproliferative, Endometrium, Macaque, Oestrogen action",
    author = "Ov Slayden and Mary Zelinski and K. Chwalisz and Richard Stouffer and Brenner, {R. M.}",
    year = "1998",
    language = "English (US)",
    volume = "13",
    pages = "269--277",
    journal = "Human Reproduction",
    issn = "0268-1161",
    publisher = "Oxford University Press",
    number = "2",

    }

    TY - JOUR

    T1 - Chronic treatment of cycling rhesus monkeys with low doses of the antiprogestin ZK 137 316

    T2 - Morphometric assessment of the uterus and oviduct

    AU - Slayden, Ov

    AU - Zelinski, Mary

    AU - Chwalisz, K.

    AU - Stouffer, Richard

    AU - Brenner, R. M.

    PY - 1998

    Y1 - 1998

    N2 - The long-term effects of the antiprogestin ZK 137 316 on reproductive tract morphology in rhesus macaques were investigated. The monkeys were injected daily (i.m.) for five menstrual cycles with vehicle or 0.01, 0.03 or 0.1 mg ZK 137 316/kg body weight. Reproductive tracts (n = 3/group) were collected during the mid-luteal phase (day 8) of the fifth cycle in the control, 0.01 and 0.03 mg/kg groups, or 6-7 days after the oestradiol peak in the 0.1 mg/kg group. ZK 137 316 treatment resulted in a dose-dependent atrophy of the endometrium, marked by reduced mitotic activity in the glands, compaction of the stroma, degradation of spiral arteries and dilation of veins. There was no effect of ZK 137 316 on myometrial or oviductal weight. Treatment with 0.1 and 0.03 mg/kg, but not 0.01 mg/kg resulted in fully ciliated and secretory oviducts, indicating a dose-dependent blockade of progesterone antagonism of oestrogen-dependent oviductal differentiation. In the endometrium, the suppressive action of progesterone on oestrogen and progestin receptors was also blocked by ZK 137 316 in a dose-dependent manner. However, endometrial atrophy appeared due to inhibition of progesterone action together with a blockade of oestrogen-dependent proliferation. The profoundly suppressed endometrium produced by chronic low-dose ZK 137 316 treatment is unlikely to support implantation. Such treatment may therefore provide a novel contraceptive modality.

    AB - The long-term effects of the antiprogestin ZK 137 316 on reproductive tract morphology in rhesus macaques were investigated. The monkeys were injected daily (i.m.) for five menstrual cycles with vehicle or 0.01, 0.03 or 0.1 mg ZK 137 316/kg body weight. Reproductive tracts (n = 3/group) were collected during the mid-luteal phase (day 8) of the fifth cycle in the control, 0.01 and 0.03 mg/kg groups, or 6-7 days after the oestradiol peak in the 0.1 mg/kg group. ZK 137 316 treatment resulted in a dose-dependent atrophy of the endometrium, marked by reduced mitotic activity in the glands, compaction of the stroma, degradation of spiral arteries and dilation of veins. There was no effect of ZK 137 316 on myometrial or oviductal weight. Treatment with 0.1 and 0.03 mg/kg, but not 0.01 mg/kg resulted in fully ciliated and secretory oviducts, indicating a dose-dependent blockade of progesterone antagonism of oestrogen-dependent oviductal differentiation. In the endometrium, the suppressive action of progesterone on oestrogen and progestin receptors was also blocked by ZK 137 316 in a dose-dependent manner. However, endometrial atrophy appeared due to inhibition of progesterone action together with a blockade of oestrogen-dependent proliferation. The profoundly suppressed endometrium produced by chronic low-dose ZK 137 316 treatment is unlikely to support implantation. Such treatment may therefore provide a novel contraceptive modality.

    KW - Antiprogestin

    KW - Antiproliferative

    KW - Endometrium

    KW - Macaque

    KW - Oestrogen action

    UR - http://www.scopus.com/inward/record.url?scp=0031913611&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=0031913611&partnerID=8YFLogxK

    M3 - Article

    C2 - 9557821

    AN - SCOPUS:0031913611

    VL - 13

    SP - 269

    EP - 277

    JO - Human Reproduction

    JF - Human Reproduction

    SN - 0268-1161

    IS - 2

    ER -